Intracellular Staining by Flow Cytometry
|Detection of IL‑22BP in Human PBMCs by Flow Cytometry. Human peripheral blood mononuclear cells (PBMCs) (A) untreated or (B) treated overnight with 250 ng/mL LPS were stained with Mouse Anti-Human IL‑22BP APC‑conjugated Monoclonal Antibody (Catalog # IC10871A) and Mouse Anti-Human CD14 PE‑conjugated Monoclonal Antibody (Catalog # FAB3832P). Quadrant markers were set based on control antibody staining (Catalog # IC0041A). To facilitate intracellular staining, cells were fixed with Flow Cytometry Fixation Buffer (Catalog # FC004) and permeabilized with Flow Cytometry Permeabilization/Wash Buffer I (Catalog # FC005). View our protocol for Staining Intracellular Molecules.|
Interleukin 22 Binding Protein (IL-22BP), also known as Cytokine Receptor Family (CRF) 2‑10, CRF2-X, and IL-22 RA2, is a secreted glycoprotein belonging to the type II cytokine receptor family. It encodes a precursor protein of 231 amino acid (aa) residues with a 21 aa putative signal peptide and five potential N-linked glycosylation sites. IL-22BP lacks a transmembrane and cytoplasmic domain and is most closely related to the extracellular domains of IL-22 R (CRF2-9) and IL-20 R (CRF2-8), sharing 33% and 34% aa sequence identity, respectively. It also shares sequence homology with the extracellular domains of IL-10 R (29%), IL-10 R beta (30%), the IFN receptors (23-25%) and tissue factor (26%). IL-22BP antagonizes IL-22 activity by specifically binding IL-22 with high affinity and blocking its interaction with the cell surface IL-22 receptor heteromeric complex composed of IL-22 R and IL-20 R. IL-22BP is expressed in multiple tissues. The highest levels of expression are found in breast, lungs and colon. The major cell types producing IL-22BP are monocytes, activated B cells and epithelial cells (1). IL-22BP is constitutively expressed by a subset of conventional dendritic cells (2). IL-22BP is regulated by the inflammasome and it has been suggested to modulate tumorigenesis in the intestine (3).